The September 9 data presentation is the key catalyst — positive topline results could drive significant upside given the 96% bullish analyst consensus and early-stage biotech profile. Monitor the webcast for safety and efficacy data; negative or ambiguous results would be bearish for this single-asset-stage company.
Price Chart
Executive Summary
Opus Genetics announced plans to present topline Phase 1/2 Cohort 1 data for OPGx-BEST1 gene therapy on September 9, 2026, with full dataset at upcoming medical meetings. This is a pre-data catalyst announcement with no actual results disclosed yet, making the event a timeline update rather than a clinical readout.
Key Facts
- Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 to be presented on September 9, 2026
- Full clinical dataset and additional analyses to be presented at upcoming medical conferences
- OPGx-BEST1 targets BEST1-related inherited retinal diseases including BVMD and ARB
- Company has seven AAV-based gene therapy programs in pipeline
- Market cap $319M with 96% analyst bullish consensus
Financial Impact
No financial data disclosed; pre-data catalyst announcement
Risk Factors
- No actual clinical data disclosed yet — results could be negative or inconclusive
- Early-stage Phase 1/2 data may not predict later-stage success
- Single-asset focus creates binary risk around OPGx-BEST1 results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354959 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 144 | $3.52 | awaiting T+60 | — | $3.32 (−5.68%) |
Oct 21, 2026 5d ago | 8-K | $3.82 | awaiting T+60 | — | $3.32 (−13.09%) |
Oct 15, 2026 11d ago | 8-K | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Oct 15, 2026 11d ago | Press Release | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.32 (−35.66%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.32 (−45.03%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.32 (−42.06%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.32 (−25.39%) |
Aug 6, 2026 11w ago | 8-K | $3.72 | awaiting T+60 | — | $3.32 (−10.75%) |
Jul 23, 2026 13w ago | 144 | $2.92 $4.05 | ▲ +38.70% | ▲ +34.15% | $3.32 (+13.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers